Red Light Therapy Wavelengths (660nm & 850nm)
Wavelength precision is the dividing line between a clinical device and a consumer gadget. 660nm hits peak cytochrome c oxidase absorption; 633nm — the cheaper LED — lands at roughly 70% of that. 850nm reaches 4–5cm into tissue versus 2–3mm for visible red. The 888-LENS uses ±2nm binning on both, spectrometer-verified. Most consumer devices ship ±10–15nm drift.
About this topic
The two primary wavelengths used in photobiomodulation are 660nm (visible red) and 850nm (near-infrared). At 660nm, photons are absorbed by the heme a3 center of cytochrome c oxidase (Complex IV) in the mitochondrial electron transport chain, with peak absorption at exactly 660nm versus approximately 70% absorption at the more common 633nm used in consumer devices. The 850nm wavelength targets the copper centers (CuA and CuB) of the same enzyme, achieving tissue penetration of 4–5cm compared to 2–3mm for visible red light. Wunsch & Matuschka (2014, RCT, n=136) demonstrated that combined 660nm+850nm treatment produces synergistic collagen density increases exceeding either wavelength alone. LED binning tolerance is critical: clinical-grade devices use ±2nm bins verified by spectrometer, while consumer devices may ship LEDs with ±10–15nm variance.